

Medical University of South Carolina, Charleston, SC
Merriman L. Dowdle, M.S., PA-C
Curriculum Vitae

Name: Merriman L. Dowdle, M.S., PA-C
Date of Birth: December 29, 1958
Office Address: Medical University of South Carolina
Division of Gastroenterology & Hepatology
Digestive Disease Center
Courtenay Dr. ART 7100A
Charleston, SC 29425
Telephone: Office: (843) 792-2301
Clinic: (843) 876-5855
Fax: (843) 876-7232

Professional Training:

12/06 Master of Science/Physician Assistance
Medical University of South Carolina, Charleston, SC
08/96 Bachelor of Science, Physician Assistant
Medical University of South Carolina, Charleston, SC
1995-1996 *Clinical Rotations:*
Pediatric Medicine: Dr. Martine Hutton and Dr. Christine Otruba
OB/GYN Medicine: Dr. Wyman Frampton and Dr. Jack Simmons, Roper Hospital
Family Medicine: Dr. Glenn Askins, McClennan-Banks Clinic
Psychiatric Medicine: Dr. Miriam DeAntonio, V.A. Hospital
Internal Medicine/Critical Care: Dr. Austin Ball, Roper Hospital
Emergency Medicine: Dr. James Tolley, Charleston Memorial Hospital
Surgical Medicine: Dr. David Baird, Roper Hospital
Preventive, Family and Nutritional Medicine: Dr. Christopher Rubel
Primary Care Medicine: Dr. Richard Rhodes and Dr. Kenneth Jones, Doctor's Care
08/91 Bachelor of Art in Studio Design/Science Concentration, Chemistry Minor, Pre-Med
University of North Carolina at Greensboro, Greensboro, NC

Faculty Appointments:

11/96-present Instructor of Medicine, Clinical Certified Physician Assistant
Medical University of South Carolina, Charleston, SC
01/99-present Clinical Instructor, Physician Assistant Program
Merriman L. Dowdle, M.S., PA-C
Curriculum Vitae

Certifications:

NCCPA National License - Primary Care and Surgical Assisting, 1996
SC State License, since 1996
SC Prescriptive Privileges, since 1997
ACLS, since 1995
BCLS, since 1995

Memberships:

American Association of Physician Assistants, since 1994
South Carolina Association of Physician Assistants, since 1994
Crohn's & Colitis Foundation of America-Professional Member, since 1997
Crohn's & Colitis Foundation of America-Board Member, Carolinas Chapter 2004
College of Health Professions, MUSC, Alumni Association board member 2000

Merits:

MUSC Blackwell Academic Merit Scholarship
 Dean's List and Dean's Honor List
 Graduated Cum Laudi

UNCG 2 Academic Merit Scholarships
 Tri Beta Biological Merit Award
 Academic Honors Biology Courses
 Honor Society
 Graduated Cum Laudi

Extramural Support:

8/01-5/02 Selected and served on the Search Committee for the new Director of the
 Physician Assistant Program.

1997-present Member of the Interviewing Selection Committee for Physician Assistant
 Students.

1998-present Liaison to the Accreditation Committee for the Physician Assistant Program.

Grant/Research:

2007-present Centocor: A Phase II/III, Multicenter, Randomized, Placebo-controlled, Double-blind
 Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy,
 Administered Intravenously, in Subjects with Moderately to Severely Active
 Ulcerative Colitis. Co-investigator with Dr. Brenda Hoffman.

Merriman L. Dowdle, M.S., PA-C
Curriculum Vitae

Grant/Research: cont.

- 2007-present Bristol-Myers Squibb: A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease who have had inadequate Clinical Response and/or Intolerance to Medical Therapy. Co-investigator with Dr. Brenda Hoffman.
- 2007-present Bristol-Myers Squibb: A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis who have had inadequate Clinical Response and/or Intolerance to Medical Therapy. Co-investigator with Dr. Brenda Hoffman.
- 2007-present Abbott Pharmaceuticals: A 5-Year Non-Interventional Registry Study of Humira® (Adalimumab) in Subjects with Moderately to Severely Active Crohn's Disease. Co-investigator with Dr. Lawrence Comerford
- 2005-07 Salix Pharmaceuticals: A Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 G BID Versus Mesalamine (5-ASA) of Asacol® 0.8 G TID in Mildly to Moderately Active Ulcerative Colitis. Co-investigator with Dr. Brenda Hoffman.
- 2005-07 UCB Pharma: - A Phase IIIb Multicenter, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor (TNF) over 26 weeks in patients suffering from Crohn's disease with prior loss of response or intolerance to infliximab. Co-investigator with Dr. Frederick Wilson
- 2005-07 PDL BioPharma: - Protocol Number 291-415 - A Phase II/III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid Refractory Ulcerative Colitis Visilizumab (Nuvion) Co-investigator with Dr. Frederick Wilson
- 2005-07 PDL BioPharma: - Protocol Number 291-417A - Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid - refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study. Co-investigator with Dr. Frederick Wilson
- 2005 Inflabloc Pharmaceuticals: - A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc® Cap in the Treatment of Patients with Moderately Active Crohn's Disease. Co-investigator with Dr. Frederick Wilson

Merriman L. Dowdle, M.S., PA-C
Curriculum Vitae

Grant/Research: cont.

- 2005-07 PDL BioPharma: - Protocol Number 291-420 - An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis. Co-investigator with Dr. Frederick Wilson
- 2003-05 Celltech. – A Phase 3 multi-national, Multi-center, double-blind, placebo-controlled, Parallel group, 26 week study to assess the safety and efficacy of the humanized anti-TNF Peg conjugate, CDP870 400 mg sc, (dosed at Weeks 0,2,4 then 4-weekly to Week 24), in the treatment of patients with active Crohn’s disease. Co-investigator with Dr. Brenda Hoffman.
- 2003-05 Celltech - A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of chronic therapy with humanized anti-TNF PEG conjugate CDP870 400 mg sc, (dosed 4-weekly to Week 50), in the treatment of patients with active Crohn’s disease who previously completed studies CDP870-031 or CDP870-032.
- 2003-05 Celltech - A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with the humanized anti-TNF PEG conjugate CDP870 400 mg sc, (dosed at weeks 0, 2, and 4 then 4-weekly to Week 48), in the treatment of patients with active Crohn’s disease who previously been withdrawn from studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn’s disease.
- 2003-06 Otsuka Maryland Research Institute, Inc. – A Phase 3 multicenter, double-blind, placebo-controlled, Parallel-arm study of the efficacy and safety of OPC-6535 tablets in the treatment of subjects with active Ulcerative Colitis. Co-investigator with Dr. Brenda Hoffman
- 2002-2003 Chugai Biopharmaceutical USA, LLC. – A 12-week multicenter, double-blind, placebo-controlled, randomized, dose-finding study to evaluate the safety and efficacy of GM-611 in patients with Diabetic Gastroparesis. Co-investigator with Dr. Brenda Hoffman.
- 2002-present Centocor Pharmaceuticals – TREAT – The Crohn’s Therapy, Resource, Evaluation and Assessment Tool Registry, a long-term observational assessment for safety outcomes specifically associated with the use of Infliximab. Principle investigator.
- 2001-05 Phase III, International, multicenter, double-blind, placebo-controlled study of the safety, efficacy and tolerability of intravenous Antegren (Natalizumab) in subjects with moderately to severely active Crohn’s disease. Co-investigator with Dr. Frederick Wilson and Dr. Brenda Hoffman

Merriman L. Dowdle, M.S., PA-C
Curriculum Vitae

Grant/Research: cont.

- 2001-02 Double-blind, randomized, 6-week, parallel-group design clinical trial in patients with mildly to moderately active ulcerative colitis to assess the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet). Co-investigator with Dr. Frederick Wilson.
- 1999-2000 Randomized, double-blind, placebo-controlled study of Paroxetine in the treatment of patients with Irritable Bowel Syndrome. Sub-investigator with Dr. Bruce Lydiard in conjunction with the MUSC Institute of Psychiatry.
- 1998-2000 Open label study with Sertraline treatment of patients with Irritable Bowel Syndrome. Sub-investigator with Dr. Bruce Lydiard and Dr. Nick Verne in conjunction with the MUSC Institute of Psychiatry and the University of Florida at Gainesville.
- 1998-99 Chugai Biopharmaceuticals, Inc. - Randomized, double blind, placebo-controlled study of GM-611 on gastric emptying and symptoms in patients with diabetic and idiopathic gastroparesis. Co-investigator with Dr. Rig Patel. Enter next phase 1/2000
- 1998-98 Glaxo Wellcome - Randomized, double blind, placebo-controlled study of Aloestron in female subjects with Irritable Bowel Syndrome. Co-investigator with Dr. Frederick Wilson.

Research Interests:

Inflammatory Bowel Disease
Irritable Bowel Syndrome
Gastroparesis, GERD, and Bowel Motility Disorders

Lectures:

- 04/08-present Guest lecturer on Inflammatory Bowel Disease for UCB Pharmaceuticals
- 04/07-present Guest lecturer on Inflammatory Bowel Disease for Abbott Pharmaceuticals
- 03/05 Coordinated and lectured for the Charleston CCFA IBD Symposium
- 10/04 Guest lecturer on Inflammatory Bowel Disease for Salix Pharmaceuticals
- 06/04 Guest lecturer on Inflammatory Bowel Disease at SC Gastroenterology Nursing Association Seminar
- 10/02-presnet Guest lecturer on Inflammatory Bowel Disease for Centocor
- 5/02 Lectured the GI Fellows on Inflammatory Bowel Disease
- 4/01 Guest lecturer on Inflammatory Bowel Disease at Southern Vistas PA Conference
- 4/00 Guest lecturer on Irritable Bowel Syndrome for GlaxoWellcome to the Physician Assistant Luncheon
- 4/00 Guest lecturer on Inflammatory Bowel Disease at Southern Vistas PA Conference
- 3/00 Guest lecturer on Inflammatory Bowel Disease at SC Gastroenterology Nursing Association Seminar
- 5/99-11/01 Coordinated and lectured for the Inflammatory Bowel Disease Partners Support Group
- 5/99 Coordinated and lectured at the Spring Inflammatory Bowel Disease Seminar for patients and families

Merriman L. Dowdle, M.S., PA-C

Curriculum Vitae

Lectures: cont.

4/98-present Coordinates and continually lectures to the Physician Assistant Program students in GI medicine

Abstracts and Presentations:

6/01 Abstract “*Altered Infusion Rates and Prophylaxis Reduce Infliximab-Related Adverse Events*” accepted for Poster Session to the American College of Gastroenterology 2001 Annual Meeting

Employment History:

1996-present *Certified Physician Assistant*, Clinical Instructor – Division of Gastroenterology, Medical University of South Carolina, Charleston, SC
Work directly with physicians and independently in patient care, clinical research and teaching. Created, coordinates and manages the Inflammatory Bowel Disease Clinic and runs 3 Infusion Therapy Centers for the Digestive Disease Center.

1993-1994 *Research Specialist*, Department of Physiology, Medical University of South Carolina, Charleston, SC
Managed research laboratory, performed experiments and assays, collected and prepared data for publication.

1992-1993 *Chemistry Specialist*, Pharmaceutical Development Center, Charleston, SC
Researched, developed, and wrote protocols for quality control stability studies of clinical trial drugs. Studies based on High Performance Liquid Chromatography.